These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28621319)

  • 41. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing.
    Basseres DS; D'Alò F; Yeap BY; Löwenberg EC; Gonzalez DA; Yasuda H; Dayaram T; Kocher ON; Godleski JJ; Richards WG; Meyerson M; Kobayashi S; Tenen DG; Halmos B; Costa DB
    Lung Cancer; 2012 Jul; 77(1):31-7. PubMed ID: 22341411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
    Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
    Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.
    Zhang Y; Ali TZ; Zhou H; D'Souza DR; Lu Y; Jaffe J; Liu Z; Passaniti A; Hamburger AW
    Cancer Res; 2010 Jan; 70(1):240-8. PubMed ID: 20048076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small cell carcinoma of the prostate: an immunohistochemical study.
    Yao JL; Madeb R; Bourne P; Lei J; Yang X; Tickoo S; Liu Z; Tan D; Cheng L; Hatem F; Huang J; Anthony di Sant'Agnese P
    Am J Surg Pathol; 2006 Jun; 30(6):705-12. PubMed ID: 16723847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.
    Asrani K; Torres AF; Woo J; Vidotto T; Tsai HK; Luo J; Corey E; Hanratty B; Coleman I; Yegnasubramanian S; De Marzo AM; Nelson PS; Haffner MC; Lotan TL
    J Pathol; 2021 Dec; 255(4):425-437. PubMed ID: 34431104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas.
    Bari MF; Brown H; Nicholson AG; Kerr KM; Gosney JR; Wallace WA; Soomro I; Muller S; Peat D; Moore JD; Ward LA; Freidin MB; Lim E; Vatish M; Snead DR
    Histopathology; 2014 Mar; 64(4):547-56. PubMed ID: 24266897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
    Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
    J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
    Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
    Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma.
    Giedl J; Büttner-Herold M; Wach S; Wullich B; Hartmann A; Agaimy A
    Hum Pathol; 2016 Sep; 55():101-7. PubMed ID: 27184483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
    Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
    Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience.
    Saclarides TJ; Szeluga D; Staren ED
    Dis Colon Rectum; 1994 Jul; 37(7):635-42. PubMed ID: 8026228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
    Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
    Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
    Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
    Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract.
    Kim IE; Amin A; Wang LJ; Cheng L; Perrino CM
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):687-693. PubMed ID: 31876605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells.
    Kazanjian A; Wallis D; Au N; Nigam R; Venken KJ; Cagle PT; Dickey BF; Bellen HJ; Gilks CB; Grimes HL
    Cancer Res; 2004 Oct; 64(19):6874-82. PubMed ID: 15466176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
    Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Shen M; Liu S; Toland A; Hsu EC; Hartono AB; Alabi BR; Aslan M; Nguyen HM; Sessions CJ; Nolley R; Shi C; Huang J; Brooks JD; Corey E; Stoyanova T
    Br J Cancer; 2023 Nov; 129(11):1818-1828. PubMed ID: 37798372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
    Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
    Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.